Market Overview

The U.S. gastric cancer diagnostics market is evolving rapidly due to the increasing burden of gastrointestinal cancers and the need for accurate, timely, and cost-effective diagnostic tools. Gastric cancer often remains asymptomatic in early stages, leading to delayed diagnosis and reduced treatment success rates. As a result, healthcare systems are prioritizing advanced screening programs and molecular diagnostic tools to improve early detection outcomes.

The U.S. gastric cancer diagnostics market was valued at USD 492.83 million in 2025 and is projected to reach USD 529.00 million in 2026. The market is expected to grow to USD 938.38 million by 2034, registering a CAGR of 7.4% during the forecast period from 2026 to 2034.

Market Scope

The U.S. gastric cancer diagnostics market demonstrates strong expansion potential across multiple dimensions:

1. Expanding Adoption of Early Screening Programs

Preventive screening initiatives are being widely implemented in high-risk populations. Increased awareness among healthcare providers and patients is contributing to higher diagnostic rates at earlier stages of the disease.

2. Growth in Molecular and Biomarker-Based Diagnostics

The integration of molecular diagnostics, including genetic testing and biomarker analysis, is improving diagnostic precision and enabling personalized treatment planning.

3. Technological Advancements in Imaging Systems

High-resolution endoscopy, enhanced CT imaging, and AI-assisted diagnostic tools are improving visualization of gastric abnormalities, leading to faster and more accurate detection.

4. Increasing Demand for Minimally Invasive Diagnostic Procedures

Patients and healthcare providers are increasingly preferring minimally invasive techniques such as capsule endoscopy and endoscopic ultrasound, which offer improved comfort and faster recovery times.

Market Opportunities

Several key opportunities are shaping the future growth of the U.S. gastric cancer diagnostics market:

1. Expansion of Precision Diagnostics

The growing focus on precision medicine presents significant opportunities for biomarker-driven diagnostic solutions that enable early and accurate detection of gastric cancer subtypes.

2. Integration of Artificial Intelligence in Diagnostics

AI-based imaging and diagnostic platforms offer opportunities to enhance interpretation accuracy, reduce workload for clinicians, and improve early detection rates through automated analysis.

3. Growth in Point-of-Care Diagnostic Solutions

The development of rapid, point-of-care testing kits for gastric cancer biomarkers is expected to improve accessibility and enable faster clinical decision-making in both urban and rural healthcare settings.

4. Rising Investment in Cancer Research and Clinical Trials

Increased funding from public and private sectors for oncology research is accelerating the development of novel diagnostic technologies and expanding the pipeline of innovative testing solutions.

Regional Analysis

The U.S. gastric cancer diagnostics market demonstrates strong regional variation, influenced by healthcare infrastructure, research intensity, and disease prevalence patterns.

• Northeast United States leads in adoption due to the presence of advanced healthcare institutions, strong research funding, and high concentration of specialized cancer centers.
• West Coast shows rapid growth driven by technological innovation, AI integration in healthcare, and strong biotechnology ecosystem.
• Midwest Region is witnessing steady adoption supported by expanding hospital networks and increasing awareness of gastrointestinal cancers.
• Southern United States is experiencing rising demand due to increasing cancer prevalence rates and expanding access to diagnostic services in community healthcare centers.

Overall, regional growth is being supported by nationwide cancer awareness campaigns, improved insurance coverage, and government-backed screening initiatives aimed at reducing cancer mortality rates.

Browse Full Insights:

https://www.polarismarketresearch.com/industry-analysis/us-gastric-cancer-diagnostics-market

Key Companies Landscape

• Abbott Laboratories
• Agilent Technologies, Inc.
• Becton, Dickinson and Company (BD)
• Bio-Rad Laboratories, Inc.
• Exact Sciences Corporation
• F. Hoffmann-La Roche Ltd.
• GE HealthCare
• Illumina, Inc.
• Mirxes Pte Ltd
• QIAGEN N.V.
• Thermo Fisher Scientific Inc.

Conclusion

The U.S. Gastric Cancer Diagnostics market is positioned for sustained growth as healthcare systems increasingly prioritize early detection and precision diagnostics. Technological advancements, rising adoption of biomarker-based testing, and expanding use of AI-driven imaging are transforming the diagnostic landscape.

With growing emphasis on preventive oncology and personalized medicine, the market is expected to continue its upward trajectory, offering significant opportunities for innovation and improved patient outcomes across the United States healthcare system.

More Trending Latest Reports By Polaris Market Research:

Psoriasis Drug Market

Dravet Syndrome Market

Plasma Protease C1-inhibitor Market

Liquid Biopsy For Early Cancer Detection And Monitoring Market

Cell Harvesting Systems Market

Inhalation Anesthesia Market

Immunotherapy Drugs Market

Europe Point of Care (PoC) Diagnostics Market